Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ID: DRG0ZBXTV)
| ADC Name |
TJ101
|
|||||
|---|---|---|---|---|---|---|
| Synonyms |
TJ101; TJ101 (Phrontline)
Click to Show/Hide
|
|||||
| Organization |
Phrontline Biopharma (Originator);Sino Biopharmaceutical
|
|||||
| Drug Status |
Phase 1
|
|||||
| Drug-to-Antibody Ratio |
8
|
|||||
| Antibody Name |
Anti-B7H3/EGFR bsAb
|
Antibody Info | ||||
| Antigen Name |
CD276 antigen; Epidermal growth factor receptor (EGFR)
|
Antigen Info | ||||
| Payload Name |
PY-4car2
|
Payload Info | ||||
| Payload Target |
DNA topoisomerase 1 (TOP1)
|
Target Info | ||||
| Linker Name |
A cleavable linker
|
Linker Info | ||||
| Conjugate Type |
Undisclosed
|
|||||
2027 Update
The disease landscape of This ADC
2027 Update
The clinical trial pipelines of This ADC
| Indication | Phase 1 | Phase 2 | Phase 3 | Approved | ||
|---|---|---|---|---|---|---|
| Unspecific solid tumor |
1 Trials
|
|||||
| Oesophageal cancer |
1 Trials
|
|||||
| Lung cancer |
1 Trials
|
|||||
| Prostate cancer |
1 Trials
|